Two first-generation EGFR tyrosine kinase inhibitors (TKI) inhibitors, erlotinib and gefitinib, are currently available for patients with advanced/incurable EGFR exon 19 deletion and exon 21, L858R, mutated NSCLC. Here, EGFR is linked to non-small cell lung carcinoma.